FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023449596> ?p ?o ?g. }

• W2023449596 endingPage "48" @default.
• W2023449596 startingPage "48" @default.
• W2023449596 abstract "<h3>Importance</h3> Myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) is curative for children with severe sickle cell disease, but toxicity may be prohibitive for adults. Nonmyeloablative transplantation has been attempted with degrees of preparative regimen intensity, but graft rejection and graft-vs-host disease remain significant. <h3>Objective</h3> To determine the efficacy, safety, and outcome on end-organ function with this low-intensity regimen for sickle cell phenotype with or without thalassemia. <h3>Design, Setting, and Participants</h3> From July 16, 2004, to October 25, 2013, 30 patients aged 16-65 years with severe disease enrolled in this nonmyeloablative transplant study, consisting of alemtuzumab (1 mg/kg in divided doses), total-body irradiation (300 cGy), sirolimus, and infusion of unmanipulated filgrastim mobilized peripheral blood stem cells (5.5-31.7 × 10⁶cells/kg) from human leukocyte antigen–matched siblings. <h3>Main Outcomes and Measures</h3> The primary end point was treatment success at 1 year after the transplant, defined as a full donor-type hemoglobin for patients with sickle cell disease and transfusion independence for patients with thalassemia. The secondary end points were the level of donor leukocyte chimerism; incidence of acute and chronic graft-vs-host disease; and sickle cell–thalassemia disease-free survival, immunologic recovery, and changes in organ function, assessed by annual brain imaging, pulmonary function, echocardiographic image, and laboratory testing. <h3>Results</h3> Twenty-nine patients survived a median 3.4 years (range, 1-8.6), with no nonrelapse mortality. One patient died from intracranial bleeding after relapse. As of October 25, 2013, 26 patients (87%) had long-term stable donor engraftment without acute or chronic graft-vs-host disease. The mean donor T-cell level was 48% (95% CI, 34%-62%); the myeloid chimerism levels, 86% (95% CI, 70%-100%). Fifteen engrafted patients discontinued immunosuppression medication with continued stable donor chimerism and no graft-vs-host disease. The normalized hemoglobin and resolution of hemolysis among engrafted patients were accompanied by stabilization in brain imaging, a reduction of echocardiographic estimates of pulmonary pressure, and allowed for phlebotomy to reduce hepatic iron. The mean annual hospitalization rate was 3.23 (95% CI, 1.83-4.63) the year before, 0.63 (95% CI, 0.26-1.01) the first year after, 0.19 (95% CI, 0-0.45) the second year after, and 0.11 (95% CI, 0.04-0.19) the third year after transplant. For patients taking long-term narcotics, the mean use per week was 639 mg (95% CI, 220-1058) of intravenous morphine–equivalent dose the week of their transplants and 140 mg (95% CI, 56-225) 6 months after transplant. There were 38 serious adverse events: pain and related management, infections, abdominal events, and sirolimus related toxic effects. <h3>Conclusions and Relevance</h3> Among 30 patients with sickle cell phenotype with or without thalassemia who underwent nonmyeloablative allogeneic HSCT, the rate of stable mixed-donor chimerism was high and allowed for complete replacement with circulating donor red blood cells among engrafted participants. Further accrual and follow-up are required to assess longer-term clinical outcomes, adverse events, and transplant tolerance. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT00061568" @default.
• W2023449596 created "2016-06-24" @default.
• W2023449596 creator A5001134935 @default.
• W2023449596 creator A5004126729 @default.
• W2023449596 creator A5007025764 @default.
• W2023449596 creator A5021207027 @default.
• W2023449596 creator A5027585674 @default.
• W2023449596 creator A5056473346 @default.
• W2023449596 creator A5063279617 @default.
• W2023449596 creator A5087536541 @default.
• W2023449596 creator A5088370534 @default.
• W2023449596 date "2014-07-02" @default.
• W2023449596 modified "2023-10-10" @default.
• W2023449596 title "Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Phenotype" @default.
• W2023449596 cites W1864748840 @default.
• W2023449596 cites W1919300793 @default.
• W2023449596 cites W1944331591 @default.
• W2023449596 cites W1969849446 @default.
• W2023449596 cites W1988779573 @default.
• W2023449596 cites W1989516517 @default.
• W2023449596 cites W2001175629 @default.
• W2023449596 cites W2001176345 @default.
• W2023449596 cites W2010193886 @default.
• W2023449596 cites W2018186485 @default.
• W2023449596 cites W2022439256 @default.
• W2023449596 cites W2024725095 @default.
• W2023449596 cites W2027816595 @default.
• W2023449596 cites W2032423016 @default.
• W2023449596 cites W2038025545 @default.
• W2023449596 cites W2042559457 @default.
• W2023449596 cites W2045234878 @default.
• W2023449596 cites W2045690184 @default.
• W2023449596 cites W2047192298 @default.
• W2023449596 cites W2049661833 @default.
• W2023449596 cites W2050007196 @default.
• W2023449596 cites W2060745772 @default.
• W2023449596 cites W2063625476 @default.
• W2023449596 cites W2065697585 @default.
• W2023449596 cites W2067823673 @default.
• W2023449596 cites W2109135798 @default.
• W2023449596 cites W2119962983 @default.
• W2023449596 cites W2126021331 @default.
• W2023449596 cites W2131921934 @default.
• W2023449596 cites W2134097317 @default.
• W2023449596 cites W2147182596 @default.
• W2023449596 cites W2148547093 @default.
• W2023449596 cites W2148669301 @default.
• W2023449596 cites W2151452421 @default.
• W2023449596 cites W2324143840 @default.
• W2023449596 cites W2334218438 @default.
• W2023449596 doi "https://doi.org/10.1001/jama.2014.7192" @default.
• W2023449596 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4698790" @default.
• W2023449596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25058217" @default.
• W2023449596 hasPublicationYear "2014" @default.
• W2023449596 type Work @default.
• W2023449596 sameAs 2023449596 @default.
• W2023449596 citedByCount "263" @default.
• W2023449596 countsByYear W20234495962013 @default.
• W2023449596 countsByYear W20234495962014 @default.
• W2023449596 countsByYear W20234495962015 @default.
• W2023449596 countsByYear W20234495962016 @default.
• W2023449596 countsByYear W20234495962017 @default.
• W2023449596 countsByYear W20234495962018 @default.
• W2023449596 countsByYear W20234495962019 @default.
• W2023449596 countsByYear W20234495962020 @default.
• W2023449596 countsByYear W20234495962021 @default.
• W2023449596 countsByYear W20234495962022 @default.
• W2023449596 countsByYear W20234495962023 @default.
• W2023449596 crossrefType "journal-article" @default.
• W2023449596 hasAuthorship W2023449596A5001134935 @default.
• W2023449596 hasAuthorship W2023449596A5004126729 @default.
• W2023449596 hasAuthorship W2023449596A5007025764 @default.
• W2023449596 hasAuthorship W2023449596A5021207027 @default.
• W2023449596 hasAuthorship W2023449596A5027585674 @default.
• W2023449596 hasAuthorship W2023449596A5056473346 @default.
• W2023449596 hasAuthorship W2023449596A5063279617 @default.
• W2023449596 hasAuthorship W2023449596A5087536541 @default.
• W2023449596 hasAuthorship W2023449596A5088370534 @default.
• W2023449596 hasBestOaLocation W20234495962 @default.
• W2023449596 hasConcept C126322002 @default.
• W2023449596 hasConcept C141071460 @default.
• W2023449596 hasConcept C203014093 @default.
• W2023449596 hasConcept C2776694085 @default.
• W2023449596 hasConcept C2776755627 @default.
• W2023449596 hasConcept C2777408962 @default.
• W2023449596 hasConcept C2777799968 @default.
• W2023449596 hasConcept C2778880498 @default.
• W2023449596 hasConcept C2779015954 @default.
• W2023449596 hasConcept C2911091166 @default.
• W2023449596 hasConcept C71924100 @default.
• W2023449596 hasConcept C90924648 @default.
• W2023449596 hasConceptScore W2023449596C126322002 @default.
• W2023449596 hasConceptScore W2023449596C141071460 @default.
• W2023449596 hasConceptScore W2023449596C203014093 @default.
• W2023449596 hasConceptScore W2023449596C2776694085 @default.
• W2023449596 hasConceptScore W2023449596C2776755627 @default.
• W2023449596 hasConceptScore W2023449596C2777408962 @default.
• W2023449596 hasConceptScore W2023449596C2777799968 @default.

• next